- Home
- HALO vs JAZZ Comparison
HALO vs JAZZ Comparison
Compare HALO & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HALO
- JAZZ
- Stock Information
- Founded
- HALO 1998
- JAZZ 2003
- Country
- HALO United States
- JAZZ Ireland
- Employees
- HALO N/A
- JAZZ N/A
- Industry
- HALO Biotechnology: Biological Products (No Diagnostic Substances)
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- HALO Health Care
- JAZZ Health Care
- Exchange
- HALO Nasdaq
- JAZZ Nasdaq
- Market Cap
- HALO 9.0B
- JAZZ 7.9B
- IPO Year
- HALO N/A
- JAZZ 2007
- Fundamental
- Price
- HALO $65.56
- JAZZ $136.58
- Analyst Decision
- HALO Buy
- JAZZ Strong Buy
- Analyst Count
- HALO 10
- JAZZ 14
- Target Price
- HALO $73.40
- JAZZ $179.21
- AVG Volume (30 Days)
- HALO 2.2M
- JAZZ 758.5K
- Earning Date
- HALO 10-30-2025
- JAZZ 11-05-2025
- Dividend Yield
- HALO N/A
- JAZZ N/A
- EPS Growth
- HALO 68.93
- JAZZ N/A
- EPS
- HALO 4.37
- JAZZ N/A
- Revenue
- HALO $1,178,672,000.00
- JAZZ $4,086,695,000.00
- Revenue This Year
- HALO $32.57
- JAZZ $5.70
- Revenue Next Year
- HALO $23.25
- JAZZ $6.16
- P/E Ratio
- HALO $15.12
- JAZZ N/A
- Revenue Growth
- HALO 34.97
- JAZZ 4.52
- 52 Week Low
- HALO $42.01
- JAZZ $95.49
- 52 Week High
- HALO $79.50
- JAZZ $148.06
- Technical
- Relative Strength Index (RSI)
- HALO 31.20
- JAZZ 63.56
- Support Level
- HALO $73.06
- JAZZ $125.79
- Resistance Level
- HALO $76.30
- JAZZ $140.39
- Average True Range (ATR)
- HALO 2.33
- JAZZ 3.18
- MACD
- HALO -1.57
- JAZZ 0.46
- Stochastic Oscillator
- HALO 3.81
- JAZZ 71.59
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.